- SourceMouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Bevacizumab F(ab")2.
- IsotypeIgG1/kappa
- SpecificityRecognizes Bevacizumab specifically, no cross reactivity with other humanized antibodies.
- Purity
>95% as determined by SDS-PAGE.
- Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
- Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
- Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 years under sterile conditions after reconstitution.
Anti-Bevacizumab Antibodies (recommended for neutralizing assay) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Anti-Bevacizumab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized bevacizumab at 0.05 µg/mL, add increasing concentrations of Anti-Bevacizumab Antibodies (recommended for neutralizing assay) (Cat. No. BEB-Y12, 10% human serum) and then add biotinylated bevacizumab at 5 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 62 ng/mL.
Demonstration of the specificity of Anti-Bevacizumab Antibodies (recommended for neutralizing assay) (Cat. No. BEB-Y12) to the bevacizumab.
Measured by its neutrlizing ability in a functional ELISA.Immobilized bevacizumab at 2 μg/mL (100 μL/well) can bind pre-mixed Anti-Bevacizumab Antibodies (recommended for neutralizing assay) (Cat. No. BEB-Y12) and Biotinylated Human VEGF 165 (Cat. No. VE5-H82Q0) with a inhibition rate of 96%.
Anti-Bevacizumab Antibodies (recommended for neutralizing assay) (mouse IgG1, Cat. No. BEB-Y12) captured on CM5 chip via anti-mouse antibodies surface, can bind human bevacizumab with an affinity constant of 0.08 nM.
- BackgroundA recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
